April 15, 2022

From the Co-Chairs, April 2022

Congress creates a new health care research agency; NCI-MATCH continues to offer treatment options; ECOG-ACRIN plans for first in-person Group Meeting since 2019
April 15, 2022

Now Enrolling: ECOG-ACRIN Opens a New NCI-MATCH Treatment Arm for dMMR and LAG-3-Positive Cancers as it Continues to Locate Patients with BRAF Mutations

The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.
April 15, 2022

Enrollment in TMIST Breast Cancer Screening Trial Surpasses Halfway Mark; Recruitment of Women from Diverse Backgrounds is Key to Success

Enrollment doubles in past 17 months due to specific efforts — Black participation rises above 20%
April 15, 2022

NCI-MATCH: The Blueprint for Future Precision Medicine Trials

In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee is offering expertise moving forward.
April 15, 2022

Trial Spotlight: Nadine Tung on the EA1181/CompassHER2 pCR Trial for HER2-Positive Breast Cancer

This study aims to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with pathologic complete response (pCR) after 12 weeks of pre-operative treatment
April 15, 2022

News in Brief, April 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
February 24, 2022

From the Co-Chairs, February 2022

Reflections on the 50th Anniversary of the National Cancer Act of 1971
February 24, 2022

Now Enrolling: EA2205 for a Rare Form of Liver Cancer

ECOG-ACRIN is leading the first randomized trial evaluating treatment strategies for patients with combined hepatocellular carcinoma-cholangiocarcinoma
February 24, 2022

Edith Mitchell Reflects on Equity Initiatives at ECOG-ACRIN

On the occasion of Black History Month, ECOG-ACRIN speaks with Edith Mitchell, MD about health equity and diversity initiatives within the Group
February 24, 2022

ECOG-ACRIN Sarcoma Working Group Builds Steam in Second Year

Kenneth Cardona, MD, FACS, of the Winship Cancer Institute at Emory University, discusses the Sarcoma Working Group’s progress to date and outlines future plans
February 24, 2022

Trial Spotlight: Nataliya Uboha on the EA2183 Trial for Esophageal and Gastric Adenocarcinoma

This randomized phase III trial explores the addition of radiotherapy to the usual treatment (chemotherapy) in patients with esophagus and stomach cancer with limited spread
February 24, 2022

Trial Results: Copanlisib in Patients with PIK3CA-Mutated Tumors

The first published results of a platform trial of PIK3CA mutations across multiple tumor types appear in the Journal of Clinical Oncology. The data are from the NCI-MATCH precision medicine trial.